Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL)
April 08 2015 - 5:05AM
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
today announced that it will present three posters, including two
late breaker abstracts, at the 50th Annual Meeting of the European
Association for the Study of the Liver (EASL) during The
International Liver Congress 2015. Poster presentations will
include Phase 1 results on ACH-3422, a NS5B nucleotide polymerase
inhibitor, and detailed results from the Phase 2 proxy study
evaluating ACH-3102, a second-generation NS5A inhibitor, and
sofosbuvir following 6- and 8-week treatment durations for
treatment-naïve genotype 1 HCV. The congress is being held April 22
– 26 in Vienna, Austria. The abstracts can be accessed on the EASL
website at https://ilc-congress.eu/ and posters will be available
following their presentation under the resources section of the
Achillion website at http://www.achillion.com.
Thursday, April 23, 2015
- LP06: Sustained virologic response after
ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: A phase 2
"proxy" study ACH102-017. ePoster Presentation, April 23-25, 7:30
am - 8:00 pm CET, Hall B ePoster Area. Lead Author: Edward Gane.
- LP27: Gane, E., et al. ACH-3422, a novel
nucleotide prodrug inhibitor of HCV NS5B polymerase. ePoster
Presentation, April 23-25, 7:30 am - 8:00 pm CET, Hall B ePoster
Area. Lead Author: Edward Gane.
- P0805: Achievement of SVR12 despite the
presence of HCV variants resistant to first generation NS5A
inhibitors in genotype-1 hepatitis C patients after 8-week therapy
of ACH-3102 in combination with sofosbuvir. ePoster Presentation,
April 23-25, 7:30 am - 8:00 pm CET, Hall B ePoster Area. Lead
Author: Wengang Yang.
About HCV
The hepatitis C virus is the most common cause of viral
hepatitis, which is an inflammation of the liver. It is currently
estimated that more than 150 million people are infected with HCV
worldwide including more than 5 million people in the United
States. Three-fourths of the HCV patient population is undiagnosed;
it is a silent epidemic and a major global health threat. Chronic
hepatitis, if left untreated, can lead to permanent liver damage
that can result in the development of liver cancer, liver failure
or death.
About Achillion Pharmaceuticals
Achillion is seeking to apply its expertise in biology and
structure-guided design and a deep understanding of patient and
clinician needs to develop innovative treatment solutions aimed at
improving patients' lives. The Company believes that its scientific
excellence, integrated capabilities and experienced team position
it to successfully achieve its goal of advancing new products along
the entire continuum from the bench to the patient. Achillion's
pipeline is currently focused on small molecule therapeutics for
infectious disease and complement-related diseases.
www.achillion.com
Cautionary Note Regarding Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other important
factors that could cause actual results to differ materially from
those indicated by such forward-looking statements. Achillion may
use words such as "expect," "anticipate," "project," "intend,"
"plan," "aim," "believe," "seek," " estimate," "can," "focus,"
"will," and "may" and similar expressions to identify such
forward-looking statements. Among the important factors that could
cause actual results to differ materially from those indicated by
such forward-looking statements are risks relating to, among other
things Achillion's ability to: demonstrate in any current and
future clinical trials the requisite safety, efficacy and
combinability of its drug candidates; advance the preclinical and
clinical development of its drug candidates, including ACH-3102,
ACH-3422, and sovaprevir, under the timelines it projects in
current and future clinical trials; obtain and maintain necessary
regulatory approvals; obtain and maintain patent protection for its
drug candidates and the freedom to operate under third party
intellectual property; establish commercial manufacturing
arrangements; identify, enter into and maintain collaboration
agreements with appropriate third-parties; compete successfully
with other companies that are seeking to develop improved therapies
for the treatment of HCV; manage expenses; manage litigation; raise
the substantial additional capital needed to achieve its business
objectives; and successfully execute on its business strategies.
These and other risks are described in the reports filed by
Achillion with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended
December 31, 2014, and its subsequent SEC filings.
In addition, any forward-looking statement in this press release
represents Achillion's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. Achillion disclaims any duty to update any
forward-looking statement, except as required by applicable
law.
CONTACT: Company Contact:
Glenn Schulman
Achillion Pharmaceuticals, Inc.
Tel. (203) 624-7000
gschulman@achillion.com
Investors:
Mary Kay Fenton
Achillion Pharmaceuticals, Inc.
Tel. (203) 624-7000
mfenton@achillion.com
Investors:
Clayton Robertson
The Trout Group, LLC
Tel. (646) 378-2964
crobertson@troutgroup.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024